The Dream Team’s approach is rooted in the idea that pancreatic cancers are, in essence, “wounds” that never heal.

Research by members of this Dream Team, and others in the field, has uncovered gene networks in tumors that are similar to those in injured tissues, where repair and regenerative mechanisms are essential to restoration of normal function. Unlike the normal system of wound healing, which has a shut-off mechanism, in tumors the process remains active, “hijacked” to constantly drive growth. The Team believes that the biological machinery involved is controlled through hot spots in a cell’s DNA called super enhancers (SE), which control not only the cancer cell but also surrounding noncancerous cells on which the cancer cells rely for support.

The SU2C–CRUK–Lustgarten Foundation Pancreatic Cancer Dream Team is working to develop new approaches to reset malfunctioning SEs in pancreatic tumors, thereby increasing the sensitivity to chemotherapy and to anticancer immune cells and pushing pancreatic tumors into lasting remission.

The team has reported the following progress:

**January 2019**

- The SU2C sponsored clinical trial of the team’s chemo-immunotherapy regimen continues to demonstrate outstanding clinical activity with 83% of patients having their tumor shrink by more than 30%. Toxicities have been tolerable and the responses are proving durable.

- The anti super-enhancer drug Minnelide continues to demonstrate antitumor activity in patients whose tumors are extremely resistant to first, second- and third-line therapies.

- Eight of the nine planned clinical trials (resulting from the scientific findings of this SU2C project) are open and accruing patients. One trial which is extremely promising is the SU2C three-drug regimen of nab-paclitaxel + gemcitabine + very high dose ascorbic acid.

- The team has made some impressive basic science discoveries including:
  
  - Finding that there might be a special healing or cancer resolution program which can be triggered to regress the disease,
  
  - Defining a new super-enhancer network target that appears to drive pancreatic cancer,
Team Progress Updates

- Developing new technologies to measure targets in very small (100 nuclei) biopsy specimens which could be very helpful in patient care, and,
- Demonstrating that a ketogenic diet dramatically increases antitumor activity of the team’s three drug regimen.

- The team continued their work on super-enhancer associated Leukemia Inhibitory Factor (LIF), which is extremely promising as an early diagnostic and measure of therapeutic effects in patients who do not secrete CA19-9. This work was recently published by Morsin Nature and also resulted in an ongoing clinical trial of the Monoclonal Antibody against LIF (NCT 03490669) for patients with advanced pancreatic and other cancers.

**June 2018**

- The team has discovered a protein that becomes more abundant when a patient develops pancreatic cancer and has developed a blood test to measure the levels of this protein. The team is gathering evidence that measuring levels of this protein can be used to assess whether a patient is responding to therapy.
- The team has opened a clinical trial testing the oral form of the anti-super-enhancer drug Minnelide.
- The team has enrolled 25 patients in a clinical trial to test adding immunotherapy and the anti-super-enhancer drug paricalcitol to chemotherapy.
- The team has reported that certain types of white cells can make pancreatic cancer more aggressive, a finding that if validated may provide additional avenues for therapies against the disease.

**December 2017**

- More patients joined a clinical trial of the anti-superenhancer agent paricalcitol plus chemo-immuno-oncology agents.
- Found that the superenhancer modulating agent Entinostat can reprogram tumor cells and cancer associated fibroblasts in the tumor.
- In preclinical studies, the anti-superenhancer agent Minnelide was found to add strong preclinical antitumor activity to the existing treatment regimen.
June 2017

- The team has identified several potential drug candidates to treat effectively pancreatic cancer stem cells.
- A phase II clinical trial for patients who have progressed on two or more prior regimens for pancreatic cancer has started.
- Two other clinical trials for patients with advanced disease are about to start in the next 2 months.

December 2016

- The Team developed a new animal model of late stage pancreatic cancer for investigation of specific new treatments including a synthetic vitamin D and the new agent, Minnelide.
- The Team has demonstrated that anti-superenhancer agents are active against pancreatic cancer stem cells and improves the efficacy of chemotherapeutics against those stem cells.

June 2016

- The Team developed new methods to identify changes in metabolism when anti-SE super enhancer agents are applied.
- The Team identified a gene that is a potential target for drug treatment of pancreatic cancer.